5-phenyl-3-isoxazolecarboxylic acid has been researched along with rifampin in 1 studies
| Studies (5-phenyl-3-isoxazolecarboxylic acid) | Trials (5-phenyl-3-isoxazolecarboxylic acid) | Recent Studies (post-2010) (5-phenyl-3-isoxazolecarboxylic acid) | Studies (rifampin) | Trials (rifampin) | Recent Studies (post-2010) (rifampin) |
|---|---|---|---|---|---|
| 16 | 0 | 7 | 20,468 | 1,499 | 6,552 |
| Protein | Taxonomy | 5-phenyl-3-isoxazolecarboxylic acid (IC50) | rifampin (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.949 | |
| Caspase-1 | Homo sapiens (human) | 8.319 | |
| Alpha-synuclein | Homo sapiens (human) | 7.1 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 0.03 | |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | 0.01 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavet, JS; Chakraborty, A; Fernandez, P; Gutierrez, MG; Kreiswith, BN; Kurepina, N; Naranjo, Y; Park, S; Perlin, DS; Pons, M; Saville, C; Schnettger, LS; Silva, APG; Tabernero, L; Thomas, EJ; Vickers, CF | 1 |
1 other study(ies) available for 5-phenyl-3-isoxazolecarboxylic acid and rifampin
| Article | Year |
|---|---|
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Design; Drug Resistance, Multiple; Female; Guinea Pigs; Macrophages; Male; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Protein Conformation; Protein Tyrosine Phosphatases; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2018 |